Protein Tyrosine Kinases

Items 1 to 25 of 338 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction
Catalog No. Product Name Application Product Information
A12027 SALE

(-)-Catechin gallate

(-)-Catechin gallate is an antioxidant constituent of green tea. At uM concentrations, inhibits VEGF-induced tyrosine phosphorylation.
A12003 SALE


(-)-Gallocatechin possesses free radical scavenging ability. It inhibits the growth and adherence of P. gingivalis onto the buccal epithelial cells.
A13232 SALE


Src Kinase inhibitor
1-NA-PP1 is a selective inhibitor of v-Src and c-Fyn as well as c-Abl


TrkB agonist
7,8-Dihydroxyflavone, a selective tyrosine kinase receptor B (neurotrophic factor/tropomyosin-receptor-kinase B; TrkB) agonist, may be used to help identify and differentiate the physiological effects and cell signaling pathways mediated by TrkB activation, such as those involving neuroprotection, memory, vasorelaxation and hypertension.


SFK inhibitor
A-419259 is an inhibitor of Src family kinases (SFK) (IC50 = 0.1 - 0.3 uM).


Lck inhibitor
A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.


Src inhibitor
A419259 trihydrochloride is an apoptosis inducing agent that inhibits Src family kinases (c-Src).
A10027 SALE

AC220 (Quizartinib)

FLT3 inhibitor
AC220 (Quizartinib) is a uniquely potent and selective FLT3 inhibitor with IC50 of 0.56 ± 0.3 nM and >10 mM for MC4-11 and A375, respectively.


PDGFR family inhibitor
AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity.

AC710 Mesylate

FLT3/KIT/PDGFRα/PDGFRβ inhibitor
AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively.
A15824 SALE

ACP-196 (Acalabrutinib)

Btk Inhibitor
ACP-196 is an orally available inhibitor of Bruton‘s tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.
A10043 SALE


EGFR inhibitor
AEE788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor that inhibits phosphorylation of the tyrosine kinases of EGFR, HER2 and VEGF2.

Afatinib dimaleate

EGFR inhibitor
Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

AG 957

p210 tyrosine kinase inhibitor
Tyrphostin AG 957 is a potent tyrosine kinase inhibitor. Selectively blocks the tyrosine kinase activity of human p210bcr-abl (Ki = 750 nM) over p140c-abl (Ki = 10 μM).
A11400 SALE

AG-1024 (Tyrphostin)

IGF-1R Inhibitor
AG-1024 (Tyrphostin) is a specific inhibitor of insulin-like growth factor-1 (IGF-1) and insulin receptor tyrosine kinase activity. Exhibits lower IC50 values for IGF-1 than for the insulin receptor. Also inhibits insulin-stimulated cellular proliferation.


tyrosine kinase inhibitor
AG-1288 is a tyrosine kinase inhibitor. Has been shown in human amnion cells (IC50 =21 mM) to block glucocorticoid-induced cytotoxicity, TNFα-induced cytotoxicity, and glucocorticoid-induced COX-2 activity.
A11022 SALE

AG-1478 (Tyrphostin AG-1478)

EGFR Inhibitor
AG-1478 (Tyrphostin AG-1478) is an inhibitor of EGFR kinase with an IC50 value of 3 nM.


EGFR inhibitor
AG-17 is an inhibitor of EGF receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.

AG-18 (Tyrphostin 23)

EGFR Inhibitor
AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 ,M in the human epidermoid carcinoma cell line A431.
A10047 SALE


EGFR inhibitor
AG 490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively).

Alofanib (RPT835)

FGFR2 Inhibitor
Alofanib is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity.

Altiratinib (DCC2701)

c-Met/VEGFR inhibitor
Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.


Eph receptor inhibitor
ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor.

AMG 208

c-Met Inhibitor
AMG 208 is a novel c-Met inhibitor that inhibits the ligand-dependent and ligand-independent activation of c-Met, inhibiting its tyrosine kinase activity.

AMG 337

MET inhibitor
AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.

Items 1 to 25 of 338 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction